Movatterモバイル変換


[0]ホーム

URL:


Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Springer full text link Springer Free PMC article
Full text links

Actions

Share

Review
.2020 Dec;198(6):897-907.
doi: 10.1007/s00408-020-00407-5. Epub 2020 Nov 11.

Update 2020: Management of Non-Small Cell Lung Cancer

Affiliations
Review

Update 2020: Management of Non-Small Cell Lung Cancer

Mariam Alexander et al. Lung.2020 Dec.

Abstract

The past decade has seen a revolution of new advances in the management of non-small cell lung cancer (NSCLC) with remarkable progresses in screening, diagnosis, and treatment. The advances in systemic treatment have been driven primarily by the development of molecularly targeted therapeutics, immune checkpoint inhibitors, and anti-angiogenic agents, all of which have transformed this field with significantly improved patient outcomes. This review will address updates in lung cancer screening, liquid biopsy, and immunotherapy in the front-line setting. We discuss recent advances and highlight the plethora of new approvals of molecular-targeted therapy for subgroups of NSCLC patients with sensitizing EGFR, ALK, ROS1, RET, BRAF V600E, MET, and NTRK alterations.

Keywords: Immune checkpoint inhibitors; Lung cancer; Targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Mariam Alexander and So Yeon Kim do not have any conflicts of interest to disclose. Haiying Cheng has received research funding from Genentech/Roche, Eisai, Spectrum, Regeneron, Bayer, and Vaccinex.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: Cancer J Clin. 2020;70(1):7–30. doi: 10.3322/caac.21590. - DOI - PubMed
    1. Couraud S, Zalcman G, Milleron B, Morin F, Souquet PJ. Lung cancer in never smokers–a review. Eur J Cancer. 2012;48(9):1299–1311. doi: 10.1016/j.ejca.2012.03.007. - DOI - PubMed
    1. Tang MS, Wu XR, Lee HW, Xia Y, Deng FM, Moreira AL, Chen LC, Huang WC, Lepor H. Electronic-cigarette smoke induces lung adenocarcinoma and bladder urothelial hyperplasia in mice. Proc Natl Acad Sci USA. 2019;116(43):21727–21731. doi: 10.1073/pnas.1911321116. - DOI - PMC - PubMed
    1. de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, Lammers JJ, Weenink C, Yousaf-Khan U, Horeweg N, van 'tWesteinde S, Prokop M, Mali WP, Hoesein FAAM, van Ooijen PMA, Aerts J, den Bakker MA, Thunnissen E, Verschakelen J, Vliegenthart R, Walter JE, Ten Haaf K, Groen HJM, Oudkerk M. Reduced lung-cancer mortality with volume CT screening in a randomized trial. New Engl J Med. 2020;382(6):503–513. doi: 10.1056/NEJMoa1911793. - DOI - PubMed
    1. Jemal A, Fedewa SA. Lung cancer screening with low-dose computed tomography in the United States-2010 to 2015. JAMA Oncol. 2017;3(9):1278–1281. doi: 10.1001/jamaoncol.2016.6416. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources

Full text links
Springer full text link Springer Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.


[8]ページ先頭

©2009-2025 Movatter.jp